Literature DB >> 11487570

Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability.

C De Jonghe1, C Esselens, S Kumar-Singh, K Craessaerts, S Serneels, F Checler, W Annaert, C Van Broeckhoven, B De Strooper.   

Abstract

Release of amyloid beta (Abeta) from the amyloid precursor protein (APP) requires cleavages by beta- and gamma-secretases and plays a crucial role in Alzheimer's disease (AD) pathogenesis. Missense mutations in the APP gene causing familial AD are clustered around the beta-, alpha- and particular gamma-secretase cleavage sites. We systematically compare in primary neurons the effect on APP processing of a series of clinical APP mutations (two of which not characterized before) located in close proximity to the gamma-secretase cleavage site. We confirm and extend previous observations showing that all these mutations (T714I, V715M, V715A, I716V, V717I and V717L) affect gamma-secretase cleavage causing an increased relative ratio of Abeta42 to Abeta40. Taking advantage of these extended series of APP mutations we were able to demonstrate an inverse correlation between these ratios and the age at onset of the disease in the different families. In addition, a subset of mutations caused the accumulation of APP C-terminal fragments indicating that these mutations also influence the stability of APP C-terminal fragments. However, it is unlikely that these fragments contribute significantly to the disease process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487570     DOI: 10.1093/hmg/10.16.1665

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  66 in total

1.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

Review 2.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

3.  Familial Alzheimer's mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site.

Authors:  Wen Chen; Eric Gamache; David J Rosenman; Jian Xie; Maria M Lopez; Yue-Ming Li; Chunyu Wang
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

4.  Effect of zinc binding on β-amyloid structure and dynamics: implications for Aβ aggregation.

Authors:  Nasrollah Rezaei-Ghaleh; Karin Giller; Stefan Becker; Markus Zweckstetter
Journal:  Biophys J       Date:  2011-09-07       Impact factor: 4.033

5.  Sphingosylphosphorylcholine attenuated β-amyloid production by reducing BACE1 expression and catalysis in PC12 cells.

Authors:  Hyoseok Yi; Seong Jin Lee; Jiyeong Lee; Chang-Seon Myung; Woo-Kyu Park; Hee-Jong Lim; Ge Hyeong Lee; Jae Yang Kong; Heeyeong Cho
Journal:  Neurochem Res       Date:  2011-06-15       Impact factor: 3.996

Review 6.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

7.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.

Authors:  Christina R Muratore; Heather C Rice; Priya Srikanth; Dana G Callahan; Taehwan Shin; Lawrence N P Benjamin; Dominic M Walsh; Dennis J Selkoe; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2014-02-12       Impact factor: 6.150

Review 8.  Exfoliation Syndrome: A Disease of Autophagy and LOXL1 Proteopathy.

Authors:  Audrey M Bernstein; Robert Ritch; Jose M Wolosin
Journal:  J Glaucoma       Date:  2018-07       Impact factor: 2.503

9.  Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature.

Authors:  Edward K Agyare; Sarah R Leonard; Geoffry L Curran; Caroline C Yu; Val J Lowe; Anant K Paravastu; Joseph F Poduslo; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2013-03-05       Impact factor: 4.939

Review 10.  Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease.

Authors:  Wioletta Rozpedek; Lukasz Markiewicz; J Alan Diehl; Dariusz Pytel; Ireneusz Majsterek
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.